T he US Food and Drug Administration (FDA) and pharmaceutical company Novo Nordisk are now in an attempt to making more ...

The EMA's main advisory committee has backed approval of Novo Nordisk's oral GLP-1 agonist Rybelsus, a key pipeline drug in its type 2 diabetes franchise. Rybelsus (semaglutide) is the first GLP-1 ...

Novo Nordisk has accused Singapore-based biotech KBP Biosciences of concealing clinical data ahead of a $1.3 billion licensing agreement between the two companies in 2023 focused on blood pressure ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.